A phase II study of Pro-NETU in patients receiving highly emetogenic chemotherapy (HEC)

Taiho Pharmaceutical Co., Ltd.1 个研究点目标入组 585 人开始时间: 待定最近更新: 2022年12月22日

试验速览

暂无简介。

研究类型: Interventional
干预模型: Central registration, multicenter, double-blind, placebo-controlled, randomized, parallel-group, comparative study
主要目的: Prevention Purpose

•Patients who are scheduled to receive cancer chemotherapy including the HEC agents
•Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1
•Patients who have provided written informed consent

•Patients with infection, diabetes mellitus, or other disease to whom it difficult to administer of DEX, which is defined in the protocol
•Patients who are unable or unwilling to cooperate in the implementation of study procedures

efficacy CR rate during the first 120 hours after the start of administration of an HEC

未报告次要终点

发起方

Loading locations...